Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BHV-1530 · 1 trial · 1 indication
Incidence and severity of TEAEs, including DLTs, SAEs and change from baseline for laboratory values, electrocardiograms (ECGs), vital signs, and physical exams to determine the safety profile, MTD, MRAD and RDR of BHV-1530 monotherapy and in combination with cemiplimab.
Incidence and severity of treatment-emergent AEs and SAEs, changes between baseline and postbaseline in laboratory values, ECGs, vital signs, and physical exams.
| Arm | Type | Description |
|---|---|---|
| BHV-1530 Monotherapy | EXPERIMENTAL | - |
| Experimental: BHV-1530 in combination with Cemiplimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BHV-1530 | DRUG | BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle |
| Cemiplimab | DRUG | cemiplimab (350 mg) will be administered as an IV infusion on Day 1 of each 21-day cycle |
Inclusion Criteria: 1. Signed, written Independent Ethics Committee (IEC)/Institutional Review Board (IRB)-approved informed consent 2. Age greater than or equal to 18 years 3. Participants consent to provide tumor tissue collected prior to study treatment, preferably from a biopsy performed after ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BHV-1530 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development as a potential therapy for advanced solid tumors. The drug is not yet approved and is being studied in a clinical trial setting to evaluate its safety and efficacy.
BHV-1530 targets FGFR3, a receptor tyrosine kinase. By targeting FGFR3, BHV-1530 is designed to interfere with signaling pathways that may drive tumor growth in certain solid tumors. This mechanism is being investigated in early-stage clinical trials for patients with advanced solid tumors.
BHV-1530 is being developed by Biohaven Ltd., a biopharmaceutical company. Biohaven is conducting clinical trials to evaluate the safety and efficacy of BHV-1530 in patients with advanced solid tumors. The company is listed on the stock exchange under the ticker symbol BHVN.
BHV-1530 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients to assess the drug's safety, tolerability, and preliminary efficacy in advanced solid tumors.
BHV-1530 is being studied in a Phase 1 clinical trial with the identifier NCT06874335. This trial, titled 'A Phase 1 Study of BHV-1530 in Advanced Solid Tumors,' is currently recruiting participants in the United States. The study aims to enroll approximately 140 patients aged 18 years and older.
BHV-1530 is a unique investigational compound developed by Biohaven Ltd. There are no alternative names provided for this drug. It is being studied specifically for its potential role in treating solid tumors and is not known to be identical to any other approved or investigational medication.